Pathogen reduction technology – is it time?
Identifieur interne : 001119 ( Main/Exploration ); précédent : 001118; suivant : 001120Pathogen reduction technology – is it time?
Auteurs : S. Kwon [Corée du Sud]Source :
- ISBT Science Series [ 1751-2816 ] ; 2016-06.
Abstract
With the application of stringent donor selection criteria and screening tests, the risk of the so‐called traditional transfusion‐transmitted infections has dramatically decreased. However, breakthrough cases are still being reported. Known pathogens that are not screened for and emerging pathogens represent a constant threat. Moreover, bacterial contamination remains the major infectious risk in blood transfusion. Pathogen reduction (PR) technology represents a proactive approach to our blood safety paradigm. PR technology for platelets and plasma has been approved in Europe for more than 10 years. Although PR efficacy against non‐enveloped viruses and spore forming bacteria is less satisfactory, these technologies show a robust PR capability for a broad spectrum of pathogens. According to current data, transfusion reactions after transfusion of treated platelets are comparable to that of non‐treated platelets and transfusion of treated platelets does not increase bleeding. Since PR technologies target nucleic acids, they inactivate leucocytes, thereby preventing non‐infectious risks like transfusion‐associated graft‐versus‐host disease and febrile non‐haemolytic transfusion reactions. Despite the multiple risks averted through pathogen reduction, the cost to implement these technologies remains a major issue. On the other hand, pathogen reduction could be an alternative to bacterial screening and gamma irradiation. Furthermore, cessation of some of the current screening items and modification of some donor exclusion criteria might be possible, especially when PR technology for red blood cells or whole blood becomes available. Therefore, if we consider all correlated efforts involved to make blood transfusion safe, the introduction of the PR technology might prove to be beneficial.
Url:
DOI: 10.1111/voxs.12273
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C23
- to stream Istex, to step Curation: 000C23
- to stream Istex, to step Checkpoint: 000025
- to stream Main, to step Merge: 001121
- to stream Main, to step Curation: 001119
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathogen reduction technology – is it time?</title><author><name sortKey="Kwon, S" sort="Kwon, S" uniqKey="Kwon S" first="S." last="Kwon">S. Kwon</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0220A0DBF16F0C1D8B6FC44350775225EDF4F624</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/voxs.12273</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-TLXPBSCB-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000C23</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C23</idno><idno type="wicri:Area/Istex/Curation">000C23</idno><idno type="wicri:Area/Istex/Checkpoint">000025</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000025</idno><idno type="wicri:doubleKey">1751-2816:2016:Kwon S:pathogen:reduction:technology</idno><idno type="wicri:Area/Main/Merge">001121</idno><idno type="wicri:Area/Main/Curation">001119</idno><idno type="wicri:Area/Main/Exploration">001119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Pathogen reduction technology – is it time?</title><author><name sortKey="Kwon, S" sort="Kwon, S" uniqKey="Kwon S" first="S." last="Kwon">S. Kwon</name><affiliation wicri:level="3"><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korean Red Cross, Seoul Nambu Blood Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Corée du Sud</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">ISBT Science Series</title><title level="j" type="sub">26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</title><title level="j" type="alt">ISBT SCIENCE SERIES</title><idno type="ISSN">1751-2816</idno><idno type="eISSN">1751-2824</idno><imprint><biblScope unit="vol">11</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="117">117</biblScope><biblScope unit="page" to="122">122</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2016-06">2016-06</date></imprint><idno type="ISSN">1751-2816</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1751-2816</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">With the application of stringent donor selection criteria and screening tests, the risk of the so‐called traditional transfusion‐transmitted infections has dramatically decreased. However, breakthrough cases are still being reported. Known pathogens that are not screened for and emerging pathogens represent a constant threat. Moreover, bacterial contamination remains the major infectious risk in blood transfusion. Pathogen reduction (PR) technology represents a proactive approach to our blood safety paradigm. PR technology for platelets and plasma has been approved in Europe for more than 10 years. Although PR efficacy against non‐enveloped viruses and spore forming bacteria is less satisfactory, these technologies show a robust PR capability for a broad spectrum of pathogens. According to current data, transfusion reactions after transfusion of treated platelets are comparable to that of non‐treated platelets and transfusion of treated platelets does not increase bleeding. Since PR technologies target nucleic acids, they inactivate leucocytes, thereby preventing non‐infectious risks like transfusion‐associated graft‐versus‐host disease and febrile non‐haemolytic transfusion reactions. Despite the multiple risks averted through pathogen reduction, the cost to implement these technologies remains a major issue. On the other hand, pathogen reduction could be an alternative to bacterial screening and gamma irradiation. Furthermore, cessation of some of the current screening items and modification of some donor exclusion criteria might be possible, especially when PR technology for red blood cells or whole blood becomes available. Therefore, if we consider all correlated efforts involved to make blood transfusion safe, the introduction of the PR technology might prove to be beneficial.</div></front></TEI><affiliations><list><country><li>Corée du Sud</li></country><region><li>Région capitale de Séoul</li></region><settlement><li>Séoul</li></settlement></list><tree><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Kwon, S" sort="Kwon, S" uniqKey="Kwon S" first="S." last="Kwon">S. Kwon</name></region><name sortKey="Kwon, S" sort="Kwon, S" uniqKey="Kwon S" first="S." last="Kwon">S. Kwon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0220A0DBF16F0C1D8B6FC44350775225EDF4F624
|texte= Pathogen reduction technology – is it time?
}}
| This area was generated with Dilib version V0.6.33. |  |